LRRK2-IN-7 NO FURTHER A MYSTERY

All enrolled clients who obtained at the least a person dose of zosuquidar or placebo all through induction were monitored to the event of adverse functions (439 individuals, 219 on zosuquidar and 210 on placebo). The most common adverse activities ended up linked to the period of prolonged and significant myelosuppression as is anticipated with in